Polycationic γ-Cyclodextrin with Amino Side Chains for a Highly Efficient Anti-Heparin Coagulant

Egyéb kategória

Today’s cyclodextrin is and Anti-Heparin Coagulant

Yes, you got it right.

From the development of Alveron Pharma, we already know it works.

This study reports an aminoethoxy-phenyl-pyridinium-modified γ-cyclodextrin (PyA-γ-CD) as a highly efficient coagulant for heparin through multivalent interactions.

PyA-γ-CD not only exhibits nearly complete neutralization activity for unfractionated heparin (UFH), but more importantly, it also effectively neutralizes three LMWHs (dalteparin (Dalte), enoxaparin (Enoxa), and nadroparin (Nadro)) with a broader therapeutic window compared to protamine.

Polycationic γ‐Cyclodextrin with Amino Side Chains for a Highly Efficient Anti‐Heparin Coagulant – An – Advanced Healthcare Materials – Wiley Online Library

Update Bridion Prescribing Information for pediatric patients from birth to less than 2 years of age

Egyéb kategória

Merck submitted supplemental new drug application which was received on June 12, 2024 by FDA for Bridion® (sugammadex) injection.

This request proposed to update Bridion Prescribing Information for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in pediatric patients from birth to less than 2 years of age.

Followed by Merck’s request, Bridion injection has been approved on December 12, 2024 for use in pediatric patients ages from birth to less than 2 years old for reversal of neuromuscular blockage induced by rocuronium bromide and vecuronium bromide.

Source: FDA 022225Orig1s014ltr.pdf

Bridion, CarboHyde

Structure-activity relationship of modified amphiphilic cationic cyclodextrins for enhanced siRNA delivery

Egyéb kategória, Today's cyclodextrin, ,

Today’s cyclodextrin was a little gift under CarboHyde’s and GENEGUT’s Christmas tree.

This study identified the structural modifications that enhance gene delivery activity of a range of cationic amphiphilic CDs, including both β- and γ-CD.

Each CDs incorporated a C12 lipid chain on the primary face of the CD. On the secondary rim, at positions C2 and C3, either primary or tertiary amine groups.

A comparative in vitro study was conducted to assess the gene silencing efficacy of these nanoparticles using the luciferase reporter gene in A549-luc cells.

Gene silencing levels for both β- and γ-CDs increased when modified with a primary amine compared to a tertiary amine group at position C2. Gene expression inhibition was further improved when the CDs were functionalized with amine functionalities at positions C2 and C3.

Modification of the secondary side of γ-cyclodextrins with two sets of primary amine functionalities via a thiopropyl linker, as compared to a triazole linker, achieved up to 80% gene knockdown, regardless of dose.

Ayse Kont, Monique Mendonça, PhD, Milo Malanga PhD, Kristóf Felegyi, Andrew Lindsay, Michael Cronin, Mary Cahill, Caitriona O’Driscoll

Structure-activity relationship of modified amphiphilic cationic cyclodextrins for enhanced siRNA delivery – ScienceDirect

cyclodextrin, cationic, carbohyde

FORMULATION DEVELOPMENT – Solubility-Enhancing Technologies in Pharmaceutical Development, a Mini-Review

Egyéb kategória

Great article in this month’s issue of Drug Development & Delivery featuring cyclodextrins and other solubilization techniques.

Ardena‘s Drug Product team, led by Vincent Levet (Director, Formulation Development and Production) and Timothy Pas (Group Leader, Formulation Development and Production), has just published this technical article that explores innovative formulation strategies aimed at addressing solubility and bioavailability challenges in poorly soluble drugs. The article focuses on advanced techniques like Amorphous Solid Dispersions (ASDs), lipid-based formulations, Nanosuspensions, and hashtag#Cyclodextrin complexes.

The team highlights how these approaches can accelerate time-to-market while ensuring optimal therapeutic outcomes.

FORMULATION DEVELOPMENT – Solubility-Enhancing Technologies in Pharmaceutical Development, a Mini-Review (drug-dev.com)

A humanized mouse that mounts mature class-switched, hypermutated and neutralizing antibody responses

Egyéb kategória

Scientists create first mouse model with complete, functional human immunesystem and a human-like gutmicrobiome that is capable of mounting specific antibody responses.

Such a model would have unlimited uses in pharma development. The work of Paolo Casali et al groundbreaking and will disrupt the animal models we use for efficacy and safety studies. How would you use this model first? I imagine studies with vaccines probably…

Nature Immunology, 5 July 2024

A humanized mouse that mounts mature class-switched, hypermutated and neutralizing antibody responses | Nature Immunology

Carbohyde blog

Anti–inflammatory effects of cyclodextrin nanoparticles enable macrophage repolarization and combat inflammation

Egyéb kategória

Today’s cyclodextrin is about the intrinsic anti-inflammatory properties of CDs.

Inflammation is an essential contributor to the pathophysiology of numerous diseases, and dysregulation of the involved signaling cascades often culminates in uncontrollable disease progression and, ultimately, chronification. Effectively addressing these disorders is challenging due to their inherent complexity and the need to mitigate inflammation while preserving essential immune functions.

Amphihilic cyclodextrin-based nanoparticles exhibit significant downregulation of crucial pro-inflammatory markers, along with changes in inflammasome activation and the lipid profile of pro-inflammatory macrophages after CD nanoparticle application. The findings of this study underscore the potential of cyclodextrin-based nanoparticles as versatile biomaterials for treating the complex pathophysiology of various acute and chronic inflammation-associated disorders.


Anti–inflammatory effects of cyclodextrin nanoparticles enable macrophage repolarization and combat inflammation | Research Square
Felix E. B. Brettner, Annika Haessler, Jonas Schreiner et al from Goethe University Frankfurt

CarboHyde blog

Cyclodextrin derivatives for the treatment of gout and hyperuricemia

Egyéb kategória

Inspiring research and patent from our collaborators at Università degli Studi di Torino and Universidad de Murcia

Adrián Matencio Durán, Francesco Trotta, Yousef Khazaei Monfared, Fabrizio Caldera, and José Manuel López Nicolás disclosed an invention in which various cyclodextrins are investigated in the therapy of gout and hyperuricemia.

WO2024133757 CYCLODEXTRIN DERIVATIVES FOR THE TREATMENT OF GOUT AND HYPERURICEMIA (wipo.int)

Stepwise Nitric Oxide Release and Antibacterial Activity of a Nitric Oxide Photodonor Hosted within Cyclodextrin Branched Polymer Nanocarriers

Egyéb kategória

Fresh from the oven, is a paper from our long-term collaboration with Università di Catania and Salvo Sortino‘s team about Cyclodextrin Branched Polymer Nanocarriers.

Encapsulation of the NO photodonor within biocompatible neutral, cationic, and anionic β-cyclodextrin branched polymers as suitable carriers leads to supramolecular nanoassemblies, which exhibit the same nature of the photochemical processes but NO photorelease performances enhanced by about 1 order of magnitude when compared with the free guest.

Antibacterial tests carried out with methicillin-resistant Staphylococcus aureus and Acinetobacter baumannii demonstrate an effective antibacterial activity exclusively under light activation and point out a differentiated role of the polymeric nanocarriers in determining the outcome of the antibacterial photodynamic action.

Stepwise Nitric Oxide Release and Antibacterial Activity of a Nitric Oxide Photodonor Hosted within Cyclodextrin Branched Polymer Nanocarriers | ACS Medicinal Chemistry Letters

Hopefully, our CSO Milo Malanga will continue to promote such flourishing collaborations.